Starling Oncology: Chernett Jorey buys 1,391 call options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Starling Oncology, Inc. (STLN) reports that ten-percent owner Chernett Jorey purchased 1,391 call options on November 11, 2026, at $0.80 per share. The options have a $4.00 exercise price, expire February 19, 2027, and cover 139,100 common shares; Jorey’s reported resulting position is 6,391 options. Jorey reported that the purchase is a matchable transaction subject to Section 16(b), calculated short-swing profit, and intends to disgorge it to the issuer.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Call Option (STLN 19FEB27 $4C) F1 | 1,391 | $0.80 | $1K |
Footnotes (1)
- F1. The reported transaction is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transaction, which the reporting person intends to disgorge to the Issuer.
Key Figures
Key Terms
Section 16(b) regulatory
short-swing profit financial
call option financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many STLN call options did Chernett Jorey buy?
What did Chernett Jorey report about short-swing profit from the STLN options transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.